2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy

Herrstedt, Jørn; Roila, Fausto; Warr, David; Celio, Luigi; Navari, Rudolph M.; Hesketh, Paul J.; Chan, Alexandre; Aapro, Matti

doi:10.1007/s00520-016-3313-0

Cited by 111 publications

(135 citation statements)

References 46 publications

Supporting

Mentioning

132

Contrasting

Unclassified

Order By: Relevance

“…Among untreated patients, 5DO is still the best fit while 5CN tops the hierarchy for experienced subjects. Moreover, partially consistent to aprepitant in ESMO guidelines, 5CN is the top antiemetic for AC‐based chemotherapy, while 5CNO displays the best ranking for no‐AC studies by surpassing 5DO. These subgroup results have verified the interchangeable positions among 5DO, 5CNO and 5CN.…”

Section: Discussionsupporting

confidence: 57%

“…However, huge difference has been observed by our network results that 5DO is probably with the highest protective effects when delayed episodes threaten. Dexamethasone plus aprepitant is recommended based on investigations which analyze delayed results of antiemetics regardless of its acute‐phase management . For fear of possible carryover effect by acute regimens (usually 5‐HT 3 RA), we redefine the categories by taking all‐phase regimens into account, which may partially contribute to the incompatibility between network and guidelines results.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparative efficacy and tolerability of antiemetic prophylaxis for adult highly emetogenic chemotherapy: A network meta‐analysis of 143 randomized controlled trials

Cheng

Cai

Shuai

et al. 2017

Intl Journal of Cancer

View full text Add to dashboard Cite

Chemotherapy-induced nausea and vomiting (CINV) is one of the commonest side-effects among cancer patients. However, there is lacking of hierarchical evidences comparing different antiemetics against highly emetogenic chemotherapy. Therefore, we conducted a network meta-analysis to investigate their comparative efficacy and tolerability. Randomized controlled trials that compared different antiemetic categories for adult highly emetogenic chemotherapy were included after searching PubMed, Web of Science, Embase and Cochrane Central. Acute-phase no emesis and no nausea were identified as primary endpoints. We made pairwise and hierarchical calculations by random-effects model. Effect sizes were presented by odds ratio and 95% confidential interval. Subgroup analysis was additionally performed. 143 randomized trials were included into pooled analysis, containing 22,776 patients and 18 antiemetic categories. 5-HT RA plus corticosteroid plus NK-1 RA plus other (5CNO) displayed best protection against both acute emesis (SUCRA: 99.7%) and nausea (95.6%). 5CNO (99.7%) and 5-HT RA plus corticosteroid plus other (5CO, 85.3%) topped subgroup hierarchies for no-naivety and anthracycline plus cyclophosphamide (AC)-based studies. On the other hand, 5-HT RA plus dopamine RA plus other (5DO) may be best fit for delayed emesis (92.0%) and nausea (92.7%). Subgroups featuring no-naivety and AC-based trials preferred 5DO (91.9%) and 5CN (88.6%), respectively. In addition, dopamine RA plus other (DO) had the lowest incidence of TRAE in most circumstances, except for AC-based subgroup where corticosteroid plus dopamine RA plus other (CDO) preponderated (69.2%). 5CNO and 5DO should be considered as first-line regimens against highly emetogenic chemotherapy induced acute and delayed CINV, respectively.

show abstract

Section: Discussionsupporting

confidence: 57%

Section: Discussionmentioning

confidence: 99%

Comparative efficacy and tolerability of antiemetic prophylaxis for adult highly emetogenic chemotherapy: A network meta‐analysis of 143 randomized controlled trials

Cheng

Cai

Shuai

et al. 2017

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Despite comprehensive antiemetic treatment guidelines [11][12][13][14], there is still an unmet clinical need to improve the prevention of CINV.…”

mentioning

confidence: 99%

“…Clinical practice guidelines recommend a combination of antiemetics of different classes for the prevention of CINV, including 5-hydroxytryptamine type 3 (5-HT 3 ) receptor antagonists, neurokinin 1 (NK-1) receptor antagonists and dexamethasone [11][12][13][14]. Granisetron and palonosetron are two of several 5-HT 3 receptor antagonist antiemetics included in antiemetic guidelines [11][12][13][14].…”

mentioning

confidence: 99%

“…Granisetron and palonosetron are two of several 5-HT 3 receptor antagonist antiemetics included in antiemetic guidelines [11][12][13][14]. A recent addition to this class is granisetron extended-release subcutaneous (GERSC; Sustol R ), a novel formulation of 2% granisetron in a viscous bioerodible Biochronomer R tri(ethylene glycol) poly(orthoester) (TEG-POE) polymer [15].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Hydration Requirements with Emetogenic Chemotherapy: Granisetron Extended-Release Subcutaneous Versus Palonosetron

Vacirca¹,

Caruana²,

Calcanes³

et al. 2018

Future Oncol.

View full text Add to dashboard Cite

Aim: This retrospective analysis evaluated chemotherapy-induced nausea and vomiting (CINV)-related hydration needs with palonosetron or granisetron extended-release subcutaneous (GERSC), approved in 2016 for CINV prevention. Materials & methods: At a community practice, CINV-related hydration per chemotherapy cycle was determined following highly (HEC) or moderately emetogenic chemotherapy (MEC) and a guideline-recommended antiemetic regimen: neurokinin 1 receptor antagonist, dexamethasone and either palonosetron only, GERSC only, or palonosetron switched to GERSC. Results: Palonosetrononly patients (n = 93) had a significantly higher mean (standard deviation) hydration rate (0.

show abstract

Gastrointestinal and Hepatic Complications in Cancer Patients

Bresalier¹,

Coronel²,

Zhang³

2022

Holland‐Frei Cancer Medicine

View full text Add to dashboard Cite

Overview Gastrointestinal and hepatic complications represent some of the most common and potentially life‐threatening disorders associated with treatment of cancer patients. The expansion of therapeutic options for these patients has been accompanied by a growing number of direct and indirect consequences which affect the rapidly dividing cells of the GI tract. Cytotoxic, immunologic, and infectious insults often act synergistically to augment toxicity. Recognition of these complications, together with proper evaluation and management are key to the well‐being of these patients.

show abstract

2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy

Cited by 111 publications

References 46 publications

Comparative efficacy and tolerability of antiemetic prophylaxis for adult highly emetogenic chemotherapy: A network meta‐analysis of 143 randomized controlled trials

Comparative efficacy and tolerability of antiemetic prophylaxis for adult highly emetogenic chemotherapy: A network meta‐analysis of 143 randomized controlled trials

Hydration Requirements with Emetogenic Chemotherapy: Granisetron Extended-Release Subcutaneous Versus Palonosetron

Gastrointestinal and Hepatic Complications in Cancer Patients

Contact Info

Product

Resources

About